New research (the Ver-A-T1D trial) presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15–19 September) shows that slow-release (SR) verapamil (360mg ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback